Tumour mutational burden and survival with molecularly matched therapy
- 4 August 2023
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 190, 112925
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancersNature Genetics, 2017
- PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic MelanomaJCO Precision Oncology, 2017
- Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical responseBlood, 2017
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung CancerNew England Journal of Medicine, 2017
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trialThe Lancet Oncology, 2015
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 MutationsNew England Journal of Medicine, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung CancerNew England Journal of Medicine, 2014
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011